Jerusalem, 17 September, 2025 (TPS-IL) — IceCure Medical Ltd. announced that Israel’s Ministry of Health has approved its XSense Cryoablation System and CryoProbes for a broad range of medical indications, including breast cancer, gynecology, oncology, and general surgery. The system, which destroys tumors using liquid-nitrogen-based freezing, offers a minimally invasive alternative to surgical tumor removal.
Already cleared by the U.S. FDA, XSense aims to accelerate patient recovery, reduce complications, and lower treatment costs.
The system joins IceCure’s ProSense platform in providing office-based, efficient tumor treatments across multiple specialties.